Health-economic impacts of age-targeted and sex-targeted Lassa fever vaccination in endemic regions of Nigeria, Guinea, Liberia, and Sierra Leone: a modelling study
Abstract
BACKGROUND: Lassa fever is an emerging zoonotic disease endemic to west Africa. Several vaccines aimed at preventing Lassa fever are currently under development, creating a need to assess how best to administer them once licensed for human use. We aimed to project the health-economic burden of Lassa fever from 2025 to 2037 across age and sex groups in subnational administrative divisions of west Africa with endemic Lassa mammarenavirus transmission and to estimate the cost-effectiveness of targeting Lassa vaccination to different risk groups. METHODS: In this vaccine-impact modelling study, we developed a mathematical model using a zoonosis risk map and epidemiological data from recent and ongoing cohort studies to predict the health-economic burden of Lassa fever across age and sex groups in endemic regions. We simulated vaccination campaigns targeting different risk groups to estimate the cost-effectiveness of various strategies for Lassa vaccine administration. Threshold vaccine costs (TVCs), which represent the break-even price per dose of vaccine administered, were estimated in international dollars (INT$ 2023), accounting for health-care costs, productivity losses, and monetised disability-adjusted life-years (DALYs) averted by vaccination. FINDINGS: Lassa fever was estimated to cause 6·23 (95% uncertainty interval (UI) 4·21-8·42) hospitalisations, 0·75 (0·48-1·10) deaths and 31·1 (17·7-52·2) DALYs per 100 000 person-years. Vaccine strategies targeting adolescents-adults aged 15-49, older adults aged 50 years and older, and women of childbearing age (WCBA) aged 15-49 years prevented, respectively, the most hospitalisations, deaths, and DALYs per 100 000 vaccine doses. Under base case assumptions, the most cost-effective strategy (greatest net monetary benefit) was untargeted vaccination for a vaccine costing INT$2 per dose, and targeting adolescents-adults at $5 per dose. At $10 per dose or more, none of the considered strategies were cost-effective. The highest TVC for a single-dose vaccine was estimated at $7·39 (95% UI 4·33-11·60) when targeting adolescents-adults, followed by $6·69 (4·17-9·85) when targeting older adults, $6·10 (3·56-9·74) when targeting WCBA, and $1·94 (1·10-3·10) when targeting children. INTERPRETATION: Targeting of adolescents-adults appears to generate the greatest health-economic value per vaccine dose. However, the most cost-effective vaccination strategy will depend on vaccine price. FUNDING: Coalition for Epidemic Preparedness Innovations.
Related
- Estimated health and economic impacts of Nutri-Score labelling in England: a modelling study
- Health impacts of US international economic sanctions: a scoping review
- Implementing enhanced recovery after surgery programmes in a healthcare facility: issues and economic impacts
- Evaluation of health and economic impacts of atmospheric PM₂.₅ in Tabriz, Iran, using BenMAP-CE and AirQ+
- Health and Economic Impacts of an Early Labor Induction Policy for High‐BMI Mothers
BibTeX
@article{smith2026healtheconomic,
title = {{Health-economic impacts of age-targeted and sex-targeted Lassa fever vaccination in endemic regions of Nigeria, Guinea, Liberia, and Sierra Leone: a modelling study}},
author = {David Smith and Mary Chriselda Antony Oliver and Katherine Holohan and Harry Street and Andrew Torkelson and Danny Asogun and Oladele Oluwafemi Ayodeji and Benedict Azuogu and Anton Camacho and William Fischer and Donald Grant and Kamji Jan and Sylvanus Okogbenin and Jefferson Sibley and David Wohl and T Déirdre Hollingsworth and Koen Pouwels},
journal = {The Lancet global health},
year = {2026},
month = oct,
doi = {10.1016/s2214-109x(25)00450-4},
url = {https://hal.science/hal-05784684v1},
note = {CC BY},
}
RIS
TY - JOUR
TI - Health-economic impacts of age-targeted and sex-targeted Lassa fever vaccination in endemic regions of Nigeria, Guinea, Liberia, and Sierra Leone: a modelling study
AU - David Smith
AU - Mary Chriselda Antony Oliver
AU - Katherine Holohan
AU - Harry Street
AU - Andrew Torkelson
AU - Danny Asogun
AU - Oladele Oluwafemi Ayodeji
AU - Benedict Azuogu
AU - Anton Camacho
AU - William Fischer
AU - Donald Grant
AU - Kamji Jan
AU - Sylvanus Okogbenin
AU - Jefferson Sibley
AU - David Wohl
AU - T Déirdre Hollingsworth
AU - Koen Pouwels
PY - 2026
DA - 2026/10/07
JO - The Lancet global health
DO - 10.1016/s2214-109x(25)00450-4
UR - https://hal.science/hal-05784684v1
AB - BACKGROUND: Lassa fever is an emerging zoonotic disease endemic to west Africa. Several vaccines aimed at preventing Lassa fever are currently under development, creating a need to assess how best to administer them once licensed for human use. We aimed to project the health-economic burden of Lassa fever from 2025 to 2037 across age and sex groups in subnational administrative divisions of west Africa with endemic Lassa mammarenavirus transmission and to estimate the cost-effectiveness of targeting Lassa vaccination to different risk groups. METHODS: In this vaccine-impact modelling study, we developed a mathematical model using a zoonosis risk map and epidemiological data from recent and ongoing cohort studies to predict the health-economic burden of Lassa fever across age and sex groups in endemic regions. We simulated vaccination campaigns targeting different risk groups to estimate the cost-effectiveness of various strategies for Lassa vaccine administration. Threshold vaccine costs (TVCs), which represent the break-even price per dose of vaccine administered, were estimated in international dollars (INT$ 2023), accounting for health-care costs, productivity losses, and monetised disability-adjusted life-years (DALYs) averted by vaccination. FINDINGS: Lassa fever was estimated to cause 6·23 (95% uncertainty interval (UI) 4·21-8·42) hospitalisations, 0·75 (0·48-1·10) deaths and 31·1 (17·7-52·2) DALYs per 100 000 person-years. Vaccine strategies targeting adolescents-adults aged 15-49, older adults aged 50 years and older, and women of childbearing age (WCBA) aged 15-49 years prevented, respectively, the most hospitalisations, deaths, and DALYs per 100 000 vaccine doses. Under base case assumptions, the most cost-effective strategy (greatest net monetary benefit) was untargeted vaccination for a vaccine costing INT$2 per dose, and targeting adolescents-adults at $5 per dose. At $10 per dose or more, none of the considered strategies were cost-effective. The highest TVC for a single-dose vaccine was estimated at $7·39 (95% UI 4·33-11·60) when targeting adolescents-adults, followed by $6·69 (4·17-9·85) when targeting older adults, $6·10 (3·56-9·74) when targeting WCBA, and $1·94 (1·10-3·10) when targeting children. INTERPRETATION: Targeting of adolescents-adults appears to generate the greatest health-economic value per vaccine dose. However, the most cost-effective vaccination strategy will depend on vaccine price. FUNDING: Coalition for Epidemic Preparedness Innovations.
SN - 2572-116X
SN - 2214-109X
ER -